识别淀粉样蛋白相关影像学异常的遗传风险
本文讨论三种抗淀粉样蛋白抗体(阿杜那单抗、仑卡奈单抗、多奈单抗)在阿尔茨海默病早期症状阶段临床试验中的疗效与安全性,重点阐述淀粉样蛋白相关影像学异常(ARIA)的两种形式(ARIA-E 和 ARIA-H)及其影像学检测方法,并探讨 ARIA 可能的病理生理机制,提出识别 ARIA 遗传风险的必要性。
要点
- 三种抗淀粉样蛋白抗体均能清除脑内β-淀粉样蛋白,在阿尔茨海默病早期症状阶段显示 modest 临床效应。
- ARIA 表现为血管源性水肿或脑沟积液(ARIA-E)或出血导致的含铁血黄素沉积(ARIA-H)。
- ARIA-E 在 FLAIR 序列上可见,ARIA-H 在铁敏感序列(T2* 或磁敏感加权成像)上显示微出血和/或表面含铁血黄素沉积。
核心结论
- 三种抗淀粉样蛋白抗体(阿杜那单抗、仑卡奈单抗、多奈单抗)在阿尔茨海默病早期症状阶段均有 modest 临床效应、清除脑内 Aβ 并显示下游分子标志物变化,但均出现 ARIA 这一不良事件。
主要发现
- 过去 2 年有 3 项抗淀粉样蛋白抗体在阿尔茨海默病中的成功试验:阿杜那单抗经加速审批途径获美国食品药品监督管理局批准但存在争议;仑卡奈单抗已获美国食品药品监督管理局批准;多奈单抗正在审批过程中。
- 所有 3 种药物以及其他几种未显示阳性效果的抗淀粉样蛋白免疫治疗(如 bapineuzemab 和 gantenerumab)均出现抗体相关影像学异常(ARIA)这一令人担忧的不良事件。
- ARIA 可表现为血管源性水肿或脑沟积液(ARIA-E)或出血导致的含铁血黄素沉积(ARIA-H)。
- ARIA-E 在液体衰减反转恢复序列上可见;ARIA-H 在铁敏感序列(T2* 或磁敏感加权成像)上显示为微出血和/或表面含铁血黄素沉积。
- ARIA 的病理生理机制尚未完全确定,可能由抗体介导的淀粉样斑块分解、释放 Aβ 沉积于血管导致脑淀粉样血管病增加或血管周围清除改变或炎症(可能通过补体激活)所致。
局限性
- ARIA 的病理生理机制尚未完全确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the last 2 years, there have been 3 successful trials of antiamyloid antibodies in Alzheimer disease (AD): aducanemab, now controversially US Food and Drug Administration-approved under the accelerated approval pathway1; lecanemab, now FDA-approved2; and donanemab, now going through the approval process.3 All 3 share a common broad mechanism, that is, antibody-mediated removal of β-amyloid (Aβ) from the brain, and this is almost certainly the basis of their therapeutic action.4 When used in the earliest symptomatic stages of AD, all have modest clinical effects, all clear Aβ from the brain, and all show evidence for some changes in molecular markers believed to be downstream of Aβ accumulation in keeping with disease modification.4 However, all these drugs-and several other antiamyloid immunotherapies that failed to show positive effects in clinical trials (e.g. bapineuzemab and gantenerumab)5,6-have the troubling adverse event of antibody-related imaging abnormalities (ARIA). ARIA can take the form of vasogenic edema or sulcal effusion (ARIA-E) or haemosiderin deposition due to hemorrhage (ARIA-H).7 In vivo, ARIA is detected using MRI: ARIA-E is visible on fluid attenuation inversion recovery sequences; ARIA-H is best seen on iron-sensitive (T2* or susceptibility-weighted imaging) as microbleeds and/or superficial hemosiderin deposition. The pathophysiology of ARIA has yet to be fully determined but may result from antibody-mediated breakdown of amyloid plaques releasing Aβ which is deposited in vessels leading to increased cerebral amyloid angiopathy or alterations in perivascular clearance or inflammation, possibly through complement activation.8.
引用
- Hardy J, Schott JM. Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities. Neurology. 2023. PMID: 38165303. doi:10.1212/WNL.0000000000208096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。